Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination

Alix-Panabieres, Catherine

doi:10.3390/books978-3-03928-699-7

dc.contributor.author	Alix-Panabieres, Catherine	*
dc.date.accessioned	2021-02-11T09:53:56Z
dc.date.available	2021-02-11T09:53:56Z
dc.date.issued	2020	*
dc.date.submitted	2020-06-09 16:38:57	*
dc.identifier	45989	*
dc.identifier.uri	https://directory.doabooks.org/handle/20.500.12854/43261
dc.description.abstract	The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system.	*
dc.language	English	*
dc.subject	R5-920	*
dc.subject.classification	thema EDItEUR::M Medicine and Nursing	en_US
dc.subject.other	n/a	*
dc.subject.other	FOLFIRINOX	*
dc.subject.other	immunofluorescence imaging	*
dc.subject.other	AR-V7	*
dc.subject.other	circulating tumour cells	*
dc.subject.other	chemoradioresistance	*
dc.subject.other	CTC-based treatment decisions	*
dc.subject.other	rVAR2	*
dc.subject.other	immunophenotyping	*
dc.subject.other	immune system	*
dc.subject.other	CellSearch®	*
dc.subject.other	flow cytometry	*
dc.subject.other	clinical trials	*
dc.subject.other	circulating tumor DNA	*
dc.subject.other	synaptophysin	*
dc.subject.other	stem cells	*
dc.subject.other	colorectal cancer	*
dc.subject.other	melanoma	*
dc.subject.other	CTC biology	*
dc.subject.other	platelets	*
dc.subject.other	AR	*
dc.subject.other	CTC capture technology	*
dc.subject.other	castration resistant prostate cancer (CRPC)	*
dc.subject.other	PD-L1 expression	*
dc.subject.other	rovalpituzumab tesirine	*
dc.subject.other	HMB-45	*
dc.subject.other	thymidylate synthase	*
dc.subject.other	ctDNA	*
dc.subject.other	tumor cell dissemination	*
dc.subject.other	solid cancers	*
dc.subject.other	metastasis	*
dc.subject.other	locally advanced rectal cancer	*
dc.subject.other	miRNA	*
dc.subject.other	epithelial-to-mesenchymal transition (EMT)	*
dc.subject.other	NSCLC	*
dc.subject.other	tumor biomarkers	*
dc.subject.other	tumor stem cells	*
dc.subject.other	circulating tumor cells	*
dc.subject.other	major histocompatibility complex class I (MHCI)	*
dc.subject.other	bone marrow	*
dc.subject.other	heterogeneity	*
dc.subject.other	cerebrospinal liquid biopsy	*
dc.subject.other	fish	*
dc.subject.other	glioma	*
dc.subject.other	in vivo flow cytometry	*
dc.subject.other	colorectal surgery	*
dc.subject.other	CellSearch	*
dc.subject.other	single-cell analysis	*
dc.subject.other	disseminated tumor cells	*
dc.subject.other	EasyCount slides	*
dc.subject.other	microsatellite instability	*
dc.subject.other	circulating plasma cells	*
dc.subject.other	circulating leukemia cells	*
dc.subject.other	ARV7	*
dc.subject.other	SLUG	*
dc.subject.other	androgen receptor	*
dc.subject.other	metastatic colorectal cancer	*
dc.subject.other	leukocyte-derived extracellular vesicles	*
dc.subject.other	prostate cancer (PCa)	*
dc.subject.other	neutrophils	*
dc.subject.other	liquid biopsy	*
dc.subject.other	enzalutamide	*
dc.subject.other	CD133	*
dc.subject.other	enrichment and detection technologies	*
dc.subject.other	biomarkers	*
dc.subject.other	immune checkpoint inhibitors	*
dc.subject.other	biomarker	*
dc.subject.other	RAD23B	*
dc.subject.other	microbiome	*
dc.subject.other	integrin B1	*
dc.subject.other	ACCEPT	*
dc.subject.other	emboli	*
dc.subject.other	small-cell lung carcinoma	*
dc.subject.other	EPISPOT	*
dc.subject.other	microfluidics	*
dc.subject.other	early breast cancer	*
dc.subject.other	circulating tumor cells (CTC)	*
dc.subject.other	tumor-initiating cells (TICs)	*
dc.subject.other	immunomodulation	*
dc.subject.other	xenograft models	*
dc.subject.other	CTC-derived xenografts	*
dc.subject.other	malaria	*
dc.subject.other	circulating tumor cells (CTCs)	*
dc.subject.other	clinical utility	*
dc.subject.other	exosomes	*
dc.subject.other	liquid surgery	*
dc.subject.other	ctRNA	*
dc.subject.other	CTCs	*
dc.subject.other	epithelial–mesenchymal transition	*
dc.subject.other	targeted therapy	*
dc.subject.other	hematological cells	*
dc.subject.other	gene expression analysis	*
dc.subject.other	hepatocellular carcinoma (HCC)	*
dc.subject.other	breast cancer	*
dc.subject.other	EpCAM enrichment	*
dc.subject.other	prostate cancer	*
dc.subject.other	CTC	*
dc.subject.other	abiraterone	*
dc.subject.other	fibronectin	*
dc.subject.other	CTC-derived ex vivo models	*
dc.subject.other	CTMat	*
dc.subject.other	chromogranin A	*
dc.subject.other	CTM	*
dc.subject.other	exosome	*
dc.title	Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination	*
dc.type	book
oapen.identifier.doi	10.3390/books978-3-03928-699-7	*
oapen.relation.isPublishedBy	46cabcaa-dd94-4bfe-87b4-55023c1b36d0	*
oapen.relation.isbn	9783039286997	*
oapen.relation.isbn	9783039286980	*
oapen.pages	366	*
oapen.edition	1st	*

Fichier(s) constituant ce document

Fichiers	Taille	Format	Vue
Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Imported or submitted locally

Afficher la notice abrégée

Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by-nc-nd/4.0/